Randy Allen Albrecht

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9100214/publications.pdf

Version: 2024-02-01

118 papers	16,682 citations	36303 51 h-index	19190 118 g-index
127 all docs	127 docs citations	127 times ranked	32174 citing authors

#	Article	IF	Citations
1	Functional Effects of Cardiomyocyte Injury in COVID-19. Journal of Virology, 2022, 96, JVI0106321.	3.4	17
2	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. Cell Host and Microbe, 2022, 30, 373-387.e7.	11.0	138
3	Advances and gaps in SARS-CoV-2 infection models. PLoS Pathogens, 2022, 18, e1010161.	4.7	61
4	Profiling Selective Packaging of Host RNA and Viral RNA Modification in SARS-CoV-2 Viral Preparations. Frontiers in Cell and Developmental Biology, 2022, 10, 768356.	3.7	2
5	Detection of Velogenic Avian Paramyxoviruses in Rock Doves in New York City, New York. Microbiology Spectrum, 2022, 10, e0206121.	3.0	2
6	Limited extent and consequences of pancreatic SARS-CoV-2 infection. Cell Reports, 2022, 38, 110508.	6.4	36
7	Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine. Microbiology Spectrum, 2022, 10, e0007822.	3.0	4
8	Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology. Clinical Infectious Diseases, 2021, 73, e4375-e4383.	5.8	13
9	Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines, 2021, 9, 40.	4.4	14
10	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Modern Pathology, 2021, 34, 1456-1467.	5.5	184
11	A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nature Biomedical Engineering, 2021, 5, 815-829.	22.5	228
12	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell, 2021, 184, 2618-2632.e17.	28.9	80
13	Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. Cell Reports Medicine, 2021, 2, 100369.	6.5	61
14	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. Human Pathology, 2021, 114, 110-119.	2.0	32
15	Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy. Nature Microbiology, 2021, 6, 1319-1333.	13.3	23
16	Interaction between NS1 and Cellular MAVS Contributes to NS1 Mitochondria Targeting. Viruses, 2021, 13, 1909.	3.3	2
17	Tox2 is required for the maintenance of GC T _{FH} cells and the generation of memory T _{FH} cells. Science Advances, 2021, 7, eabj1249.	10.3	12
18	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infectious Diseases, The, 2020, 20, 80-91.	9.1	103

#	Article	IF	Citations
19	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, 2020, 586, 113-119.	27.8	672
20	Animal models for COVID-19. Nature, 2020, 586, 509-515.	27.8	705
21	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	4.4	61
22	Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 2020, 181, 1036-1045.e9.	28.9	3,572
23	An In Vitro Microneutralization Assay for SARSâ€CoVâ€2 Serology and Drug Screening. Current Protocols in Microbiology, 2020, 58, e108.	6.5	165
24	Viral Determinants in H5N1 Influenza A Virus Enable Productive Infection of HeLa Cells. Journal of Virology, 2020, 94, .	3.4	5
25	Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection. Nature Communications, 2020, 11, 2537.	12.8	72
26	Mass Cytometry Defines Virus-Specific CD4+ T Cells in Influenza Vaccination. ImmunoHorizons, 2020, 4, 774-788.	1.8	3
27	Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. Frontiers in Immunology, 2019, 10, 2005.	4.8	48
28	Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1. Journal of Virology, 2019, 93, .	3.4	65
29	Host-Specific NS5 Ubiquitination Determines Yellow Fever Virus Tropism. Journal of Virology, 2019, 93, .	3.4	18
30	Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Frontiers in Immunology, 2019, 10, 756.	4.8	48
31	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. Npj Vaccines, 2019, 4, 51.	6.0	18
32	Diminished B-Cell Response After Repeat Influenza Vaccination. Journal of Infectious Diseases, 2019, 219, 1586-1595.	4.0	36
33	Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. Journal of Clinical Investigation, 2018, 128, 4992-4996.	8.2	51
34	Influenza virus infection causes global RNAPII termination defects. Nature Structural and Molecular Biology, 2018, 25, 885-893.	8.2	48
35	Analyses of Cellular Immune Responses in Ferrets Following Influenza Virus Infection. Methods in Molecular Biology, 2018, 1836, 513-530.	0.9	8
36	A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study. Vaccines, 2018, 6, 47.	4.4	28

#	Article	IF	Citations
37	Moving Forward: Recent Developments for the Ferret Biomedical Research Model. MBio, 2018, 9, .	4.1	52
38	Transcription Elongation Can Affect Genome 3D Structure. Cell, 2018, 174, 1522-1536.e22.	28.9	369
39	Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses. Methods in Molecular Biology, 2018, 1836, 487-511.	0.9	5
40	Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nature Immunology, 2017, 18, 464-473.	14.5	131
41	The RNA Exosome Syncs IAV-RNAPII Transcription to Promote Viral Ribogenesis and Infectivity. Cell, 2017, 169, 679-692.e14.	28.9	48
42	Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 296-304.e2.	0.4	39
43	Timing of Influenza Vaccine Response in Patients That Receive Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, S143-S144.	2.0	1
44	Constitutive resistance to viral infection in human CD141 ⁺ dendritic cells. Science Immunology, 2017, 2, .	11.9	99
45	A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. Npj Vaccines, 2017, 2, 26.	6.0	113
46	Pandemic H1N1 influenza A viruses suppress immunogenic RIPK3-driven dendritic cell death. Nature Communications, 2017, 8, 1931.	12.8	44
47	Endothelial cell tropism is a determinant of H5N1 pathogenesis in mammalian species. PLoS Pathogens, 2017, 13, e1006270.	4.7	49
48	A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses. PLoS Pathogens, 2017, 13, e1006258.	4.7	200
49	Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection. PLoS Pathogens, 2016, 12, e1005578.	4.7	124
50	Flow Cytometric and Cytokine ELISpot Approaches To Characterize the Cell-Mediated Immune Response in Ferrets following Influenza Virus Infection. Journal of Virology, 2016, 90, 7991-8004.	3.4	33
51	A point mutation in the polymerase protein PB2 allows a reassortant H9N2 influenza isolate of wild-bird origin to replicate in human cells. Infection, Genetics and Evolution, 2016, 41, 279-288.	2.3	4
52	ICOS+PD-1+CXCR3+ T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination. Scientific Reports, 2016, 6, 26494.	3.3	139
53	Macroautophagy Proteins Control MHC Class I Levels on Dendritic Cells and Shape Anti-viral CD8 + TÂCell Responses. Cell Reports, 2016, 15, 1076-1087.	6.4	130
54	Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine. Vaccine, 2016, 34, 1363-1369.	3.8	7

#	Article	IF	Citations
55	Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets. Journal of Virology, 2016, 90, 3268-3273.	3.4	69
56	H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. Journal of Clinical Investigation, 2016, 126, 1482-1494.	8.2	62
57	Meta- and Orthogonal Integration of Influenza â€œOMICsâ€•Data Defines a Role for UBR4 in Virus Budding. Cell Host and Microbe, 2015, 18, 723-735.	11.0	868
58	The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA. Journal of Virology, 2015, 89, 2241-2252.	3.4	56
59	Human Dendritic Cell Response Signatures Distinguish 1918, Pandemic, and Seasonal H1N1 Influenza Viruses. Journal of Virology, 2015, 89, 10190-10205.	3.4	27
60	Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science, 2015, 348, 448-453.	12.6	389
61	Interactive Big Data Resource to Elucidate Human Immune Pathways and Diseases. Immunity, 2015, 43, 605-614.	14.3	49
62	Distinct Patterns of B-Cell Activation and Priming by Natural Influenza Virus Infection Versus Inactivated Influenza Vaccination. Journal of Infectious Diseases, 2015, 211, 1051-1059.	4.0	27
63	FluzoneÂ® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood, 2015, 126, 3058-3058.	1.4	1
64	Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge. Journal of Virology, 2014, 88, 3976-3985.	3.4	52
65	A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-Î²-amyloid antibody responses in mice with pre-existing virus specific memory. Journal of Neuroimmunology, 2014, 277, 77-84.	2.3	4
66	Turkey Versus Guinea Pig Red Blood Cells: Hemagglutination Differences Alter Hemagglutination Inhibition Responses Against Influenza A/H1N1. Viral Immunology, 2014, 27, 174-178.	1.3	23
67	Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Virus Vaccine Assessment. Vaccine Journal, 2014, 21, 1668-1680.	3.1	26
68	The origin of the PB1 segment of swine influenza A virus subtype H1N2 determines viral pathogenicity in mice. Virus Research, 2014, 188, 97-102.	2.2	6
69	Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine Correlate With the Kinetics and Magnitude of Interferon Signaling in Children. Journal of Infectious Diseases, 2014, 210, 224-233.	4.0	69
70	Model of influenza A virus infection: Dynamics of viral antagonism and innate immune response. Journal of Theoretical Biology, 2014, 351, 47-57.	1.7	17
71	Influenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host. Cell Host and Microbe, 2014, 16, 691-700.	11.0	215
72	Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets. Journal of Virology, 2014, 88, 3432-3442.	3.4	128

#	ARTICLE	IF	CITATIONS
73	Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements. Cell Host and Microbe, 2014, 16, 105-114.	11.0	246
74	Distinct Cross-reactive B-Cell Responses to Live Attenuated and Inactivated Influenza Vaccines. Journal of Infectious Diseases, 2014, 210, 865-874.	4.0	26
75	Differential Requirement for the IKKÎ²/NF-ÎºB Signaling Module in Regulating TLR- versus RLR-Induced Type 1 IFN Expression in Dendritic Cells. Journal of Immunology, 2014, 193, 2538-2545.	0.8	17
76	Mucosal Polyinosinic-Polycytidylic Acid Improves Protection Elicited by Replicating Influenza Vaccines via Enhanced Dendritic Cell Function and T Cell Immunity. Journal of Immunology, 2014, 193, 1324-1332.	0.8	42
77	One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine, 2014, 32, 355-362.	3.8	59
78	Effect of Cholecalciferol Supplementation on Inflammation and Cellular Alloimmunity in Hemodialysis Patients: Data from a Randomized Controlled Pilot Trial. PLoS ONE, 2014, 9, e109998.	2.5	13
79	MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nature Biotechnology, 2013, 31, 844-847.	17.5	77
80	Accumulation of CD11b+Gr-1+ cells in the lung, blood and bone marrow of mice infected with highly pathogenic H5N1 and H1N1 influenza viruses. Archives of Virology, 2013, 158, 1305-1322.	2.1	17
81	Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses. Journal of Virology, 2013, 87, 10435-10446.	3.4	174
82	Mouse Dendritic Cell (DC) Influenza Virus Infectivity Is Much Lower than That for Human DCs and Is Hemagglutinin Subtype Dependent. Journal of Virology, 2013, 87, 1916-1918.	3.4	15
83	H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice. Journal of Virology, 2013, 87, 4728-4737.	3.4	138
84	Glycosylations in the Globular Head of the Hemagglutinin Protein Modulate the Virulence and Antigenic Properties of the H1N1 Influenza Viruses. Science Translational Medicine, 2013, 5, 187ra70.	12.4	107
85	Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs. Journal of Virology, 2013, 87, 7793-7804.	3.4	73
86	Substitutions T200A and E227A in the Hemagglutinin of Pandemic 2009 Influenza A Virus Increase Lethality but Decrease Transmission. Journal of Virology, 2013, 87, 6507-6511.	3.4	7
87	Protection against Lethal Influenza with a Viral Mimic. Journal of Virology, 2013, 87, 8591-8605.	3.4	60
88	Induction of ICOS ⁺ CXCR3 ⁺ CXCR5 ⁺ T _H Cells Correlates with Antibody Responses to Influenza Vaccination. Science Translational Medicine, 2013, 5, 176ra32.	12.4	547
89	Species-Specific Inhibition of RIG-I Ubiquitination and IFN Induction by the Influenza A Virus NS1 Protein. PLoS Pathogens, 2012, 8, e1003059.	4.7	273
90	Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses. Journal of Virology, 2012, 86, 6334-6340.	3.4	57

#	Article	IF	Citations
91	Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes. Journal of Virology, 2012, 86, 5774-5781.	3.4	241
92	Suppression of the antiviral response by an influenza histone mimic. Nature, 2012, 483, 428-433.	27.8	269
93	Major Histocompatibility Complex Class II Expression and Hemagglutinin Subtype Influence the Infectivity of Type A Influenza Virus for Respiratory Dendritic Cells. Journal of Virology, 2011, 85, 11955-11963.	3.4	18
94	Programming the magnitude and persistence of antibody responses with innate immunity. Nature, 2011, 470, 543-547.	27.8	847
95	The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. Journal of Translational Medicine, 2011, 9, 127.	4.4	14
96	Host- and Strain-Specific Regulation of Influenza Virus Polymerase Activity by Interacting Cellular Proteins. MBio, 2011, 2, .	4.1	145
97	The M Segment of the 2009 New Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission Efficiency in the Guinea Pig Model. Journal of Virology, 2011, 85, 11235-11241.	3.4	127
98	Extrapulmonary tissue responses in cynomolgus macaques (Macaca fascicularis) infected with highly pathogenic avian influenza A (H5N1) virus. Archives of Virology, 2010, 155, 905-914.	2.1	29
99	Complete-Proteome Mapping of Human Influenza A Adaptive Mutations: Implications for Human Transmissibility of Zoonotic Strains. PLoS ONE, 2010, 5, e9025.	2.5	85
100	1918 and 2009 H1N1 influenza viruses are not pathogenic in birds. Journal of General Virology, 2010, 91, 339-342.	2.9	9
101	Macaque Proteome Response to Highly Pathogenic Avian Influenza and 1918 Reassortant Influenza Virus Infections. Journal of Virology, 2010, 84, 12058-12068.	3.4	36
102	Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models. Journal of Virology, 2010, 84, 11219-11226.	3.4	94
103	NF-Î°B RelA Subunit Is Crucial for Early IFN-Î² Expression and Resistance to RNA Virus Replication. Journal of Immunology, 2010, 185, 1720-1729.	0.8	119
104	Innate immune evasion strategies of influenza viruses. Future Microbiology, 2010, 5, 23-41.	2.0	148
105	Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3455-3460.	7.1	328
106	Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza. Journal of Virology, 2009, 83, 1742-1753.	3.4	217
107	Experimental Infection of Pigs with the Human 1918 Pandemic Influenza Virus. Journal of Virology, 2009, 83, 4287-4296.	3.4	56
108	The NS1 Protein of the 1918 Pandemic Influenza Virus Blocks Host Interferon and Lipid Metabolism Pathways. Journal of Virology, 2009, 83, 10557-10570.	3.4	63

#	Article	IF	Citations
109	Influenza A Virus NS1 Targets the Ubiquitin Ligase TRIM25 to Evade Recognition by the Host Viral RNA Sensor RIG-I. Cell Host and Microbe, 2009, 5, 439-449.	11.0	737
110	Matrix Protein 2 of Influenza A Virus Blocks Autophagosome Fusion with Lysosomes. Cell Host and Microbe, 2009, 6, 367-380.	11.0	454
111	The Unique IR2 Protein of Equine Herpesvirus 1 Negatively Regulates Viral Gene Expression. Journal of Virology, 2006, 80, 5041-5049.	3.4	25
112	The EICP27 protein of equine herpesvirus 1 is recruited to viral promoters by its interaction with the immediate-early protein. Virology, 2005, 333, 74-87.	2.4	16
113	A Negative Regulatory Element (Base Pairs â˜204 to â˜177) of the EICP0 Promoter of Equine Herpesvirus 1 Abolishes the EICP0 Protein's trans -Activation of Its Own Promoter. Journal of Virology, 2004, 78, 11696-11706.	3.4	11
114	The equine herpesvirus 1 EICP27 protein enhances gene expression via an interaction with TATA box-binding protein. Virology, 2004, 324, 311-326.	2.4	17
115	Direct interaction of TFIIB and the IE protein of equine herpesvirus 1 is required for maximal trans-activation function. Virology, 2003, 316, 302-312.	2.4	16
116	Interaction of the Equine Herpesvirus 1 EICP0 Protein with the Immediate-Early (IE) Protein, TFIIB, and TBP May Mediate the Antagonism between the IE and EICP0 Proteins. Journal of Virology, 2003, 77, 2675-2685.	3.4	25
117	Mapping the Sequences That Mediate Interaction of the Equine Herpesvirus 1 Immediate-Early Protein and Human TFIIB. Journal of Virology, 2001, 75, 10219-10230.	3.4	24
118	Suppression of Innate Immunity by Orthomyxoviruses. , 0, , 267-286.		1